Back

ABDX

0.00%
NEUTRAL

Abingdon Health to Launch Innovative Saliva-Based Pregnancy Test in Germany

Why we think this is neutral

The RNS announcement details the launch of Salistick™, a new saliva-based pregnancy test, in Germany and other European markets. While this is a positive development for the company, it does not contain any of the mandatory news types that would require a more detailed analysis. Therefore, the sentiment is assessed as neutral.

Key Points

  • Salistick™ to be launched in Germany with leading retailers
  • Initial purchase order for 70,000 tests received
  • Salistick™ is a rapid saliva-based pregnancy test that offers a new and improved user-experience

Summary

The healthcare company is expanding the distribution of its innovative saliva-based pregnancy test to Germany and other European markets.

Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of rapid tests, has announced the extension of its distribution agreement with Salignostics to launch an own-branded version of Salistick™, the first saliva-based pregnancy test, in Germany, Poland and Austria. The company has received an initial purchase order for 70,000 tests, with further orders anticipated during 2025.

Key Dates

Q2 2025
Launch of Salistick™ in Germany and other European markets
GENERAL UPDATE